Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 4:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 14,953 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Digestive System Clear all
Completed Not applicable Interventional

Treatment of Depressed Adolescents With Physical Illness

NCT00446238
View directory record Official record
Conditions
Inflammatory Bowel Disease, Depression
Interventions
Cognitive Behavioral Therapy, Standard of Community Care Treatment
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
11 Years to 17 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
2
States / cities
Boston, Massachusetts • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 20, 2014 · Synced Oct 25, 2026, 4:17 AM EDT
Terminated Phase 2 Interventional Results available

A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer

NCT03165721
View directory record Official record
Conditions
Paraganglioma, Gastrointestinal Stromal Tumors, Carcinoma, Renal Cell, Renal Neoplasms, Pheochromocytoma
Interventions
SGI-110 (guadecitabine)
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years to 99 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Oct 25, 2026, 4:17 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Efficacy of Voice Treatment for Parkinson's Disease

NCT00123084
View directory record Official record
Conditions
Parkinson's Disease, Dysphagia, Dysarthria
Interventions
Voice/Respiration Treatment, Speech/Articulation Treatment
Behavioral
Lead sponsor
University of Colorado, Boulder
Other
Eligibility
45 Years to 85 Years
Enrollment
620 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2012
U.S. locations
2
States / cities
Denver, Colorado • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 31, 2018 · Synced Oct 25, 2026, 4:17 AM EDT
Terminated Phase 2 Interventional Results available

An Open Label Safety and Tolerability Study of AIN457 in Patients With Moderate to Severe Crohn's Disease

NCT01009281
View directory record Official record
Conditions
Crohn's Disease, Inflammatory Bowel Disease
Interventions
AIN457
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
5
States / cities
Bristol, Connecticut • Great Neck, New York • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2021 · Synced Oct 25, 2026, 4:17 AM EDT
Not listed Not applicable Interventional

Use of Pedometer Following Radical Cystectomy

NCT04305730
View directory record Official record
Conditions
Bladder Cancer, Ileus, Narcotic Use
Interventions
Use of a pedometer following surgery, Standard of care
Behavioral
Lead sponsor
Benaroya Research Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 16, 2021 · Synced Oct 25, 2026, 4:17 AM EDT
Completed Phase 4 Interventional Results available

Enteric-coated Mycophenolate Sodium (EC-MPS) and Mycophenolate Mofetil (MMF) in Renal Transplant Patients With Gastrointestinal (GI) Intolerance

NCT00400400
View directory record Official record
Conditions
Renal Transplantation
Interventions
Enteric-coated mycophenolate sodium (EC-MPS), Mycophenolate mofetil, Placebo to mycophenolate sodium, Placebo to mycophenolate mofetil
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
53
States / cities
Phoenix, Arizona • Los Angeles, California • Sacramento, California + 40 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2011 · Synced Oct 25, 2026, 4:17 AM EDT
Completed Phase 2 Interventional

Study of Gemcitabine and Abraxane to Treat Potentially Operable Pancreatic Cancer

NCT01298011
View directory record Official record
Conditions
Resectable Pancreatic Cancer
Interventions
Gemcitabine and Abraxane
Drug
Lead sponsor
Pancreatic Cancer Research Team
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
4
States / cities
Scottsdale, Arizona • Grand Rapids, Michigan • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2015 · Synced Oct 25, 2026, 4:17 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Prospective Randomized Trial of Moderate vs Deep Neuromuscular Blockade During Laparoscopic Ventral Hernia Repair

NCT03201744
View directory record Official record
Conditions
Hernia, Ventral, Neuromuscular Blockade, Pneumoperitoneum
Interventions
Patients will be randomized to moderate (TOF 1-2) or deep (post tetanic count 1-2) relaxation. Low pressure insufflation (start pressure set at 8 mm Hg)
Procedure
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 25, 2026, 4:17 AM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety of Oral BT-11 in Moderate to Severe Crohn's Disease

NCT03870334
View directory record Official record
Conditions
Crohn's Disease
Interventions
BT-11 880 mg, Placebo
Drug
Lead sponsor
NImmune Biopharma
Industry
Eligibility
18 Years to 75 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 4, 2023 · Synced Oct 25, 2026, 4:17 AM EDT
Active, not recruiting Phase 2 Interventional

RIC-NEC Randomized Controlled Trial

NCT05279664
View directory record Official record
Conditions
Necrotizing Enterocolitis
Interventions
Remote ischemic conditioning (RIC) + Standard of Care for NEC, Standard of Care for NEC
Other
Lead sponsor
The Hospital for Sick Children
Other
Eligibility
0 Weeks and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Oct 25, 2026, 4:17 AM EDT
Withdrawn Phase 1 Interventional

A Phase 1b Proof-of-concept Trial Exploring the Effects of FE 999322 and FE 999324 in Adults With Mild to Moderate Ulcerative Colitis

NCT06260267
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Microbiota suspension, Microbiota capsule, Placebo suspension, Placebo capsule
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
10
States / cities
North Little Rock, Arkansas • Hamden, Connecticut • Inverness, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2024 · Synced Oct 25, 2026, 4:17 AM EDT
Terminated Phase 2 Interventional Results available

A Study Evaluating Treatment Intensification With ABI-H0731 in Participants With Chronic Hepatitis B Infection on Nucleos(t)Ide Reverse Transcriptase Inhibitors

NCT04454567
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
ABI-H0731, Placebo, NrtI
Drug
Lead sponsor
Assembly Biosciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
9
States / cities
Los Angeles, California • Pasadena, California • San Diego, California + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2022 · Synced Oct 25, 2026, 4:17 AM EDT
Active, not recruiting Phase 2 Interventional

Sorafenib Plus Doxorubicin in Patients With Advanced Hepatocellular Carcinoma With Disease Progression on Sorafenib

NCT01840592
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Sorafenib, Doxorubicin
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
6
States / cities
Basking Ridge, New Jersey • Commack, New York • Harrison, New York + 3 more
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 25, 2026, 4:17 AM EDT
Terminated Phase 2 Interventional Results available

Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer

NCT03333486
View directory record Official record
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Leukemia in Remission, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Myeloid Leukemia With FLT3/ITD Mutation, Acute Myeloid Leukemia With Gene Mutations, Aplastic Anemia, B-Cell Non-Hodgkin Lymphoma, CD40 Ligand Deficiency, Chronic Granulomatous Disease, Chronic Leukemia in Remission, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Myelomonocytic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Congenital Amegakaryocytic Thrombocytopenia, Congenital Neutropenia, Congenital Pure Red Cell Aplasia, Glanzmann Thrombasthenia, Immunodeficiency Syndrome, Myelodysplastic Syndrome, Myelofibrosis, Myeloproliferative Neoplasm, Paroxysmal Nocturnal Hemoglobinuria, Plasma Cell Myeloma, Polycythemia Vera, Recurrent Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndrome, Severe Aplastic Anemia, Shwachman-Diamond Syndrome, Sickle Cell Disease, T-Cell Non-Hodgkin Lymphoma, Thalassemia, Waldenstrom Macroglobulinemia, Wiskott-Aldrich Syndrome
Interventions
Cyclophosphamide, Fludarabine Phosphate, Laboratory Biomarker Analysis, Peripheral Blood Stem Cell Transplantation, Total-Body Irradiation
Drug · Other · Procedure + 1 more
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
1 Year to 75 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jul 4, 2025 · Synced Oct 25, 2026, 4:17 AM EDT
Recruiting Phase 4 Interventional

The Use of High Bile-binding Foods to Reduce Upper Gastrointestinal Bile Acid Concentrations (Aim 1)

NCT07303738
View directory record Official record
Conditions
Feeding Difficulties, Aspiration, Gastrostomy
Interventions
amino acid based formula (e.g. Elecare Jr), low bile acid binding blenderized diet (e.g. Kate Farms), high bile acid binding blenderized diet
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
5 Years to 21 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 25, 2026, 4:17 AM EDT
Completed No phase listed Observational

Prevalence of Lymphoma in IBD

NCT00577538
View directory record Official record
Conditions
Lymphoma, Inflammatory Bowel Disease
Interventions
Not listed
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 10, 2015 · Synced Oct 25, 2026, 4:17 AM EDT
Recruiting No phase listed Observational

Depth of Maximal Ileal Insertion During Retrograde Enteroscopy With TTS Balloon

NCT04646083
View directory record Official record
Conditions
Obscure Gastrointestinal Bleeding, Anemia, Iron Deficiency
Interventions
Not listed
Lead sponsor
Texas Tech University Health Sciences Center, El Paso
Other
Eligibility
18 Years to 90 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
El Paso, Texas
Source: ClinicalTrials.gov public record
Updated Jun 18, 2025 · Synced Oct 25, 2026, 4:17 AM EDT
Completed Phase 1 Interventional

Sorafenib Tosylate and Chemoembolization in Treating Patients With Unresectable Liver Cancer

NCT01042041
View directory record Official record
Conditions
Hepatocellular Carcinoma, Liver Cancer, Localized Unresectable Liver Cancer
Interventions
sorafenib tosylate, doxorubicin hydrochloride, cisplatin, mitomycin C, transarterial chemoembolization, hepatic artery embolization
Drug · Procedure
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 26, 2013 · Synced Oct 25, 2026, 4:17 AM EDT
Completed Phase 2 Interventional

A 12-week Study Treating Participants Who Have alpha1-antitrypsin-related COPD With Alvelestat (MPH966) or Placebo.

NCT03636347
View directory record Official record
Conditions
Alpha 1-Antitrypsin Deficiency, Emphysema, COPD
Interventions
Placebo Oral Tablet, Alvelestat oral tablet - dose 1, Alvelestat oral tablet - dose 2
Drug
Lead sponsor
Mereo BioPharma
Industry
Eligibility
18 Years to 75 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
4
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2022 · Synced Oct 25, 2026, 4:17 AM EDT
Completed Phase 2 Interventional

VX-222 + Telaprevir + Ribavirin for 12 or 16 Weeks in Treatment-Naive Subjects With Genotype 1a Hepatitis C

NCT01581138
View directory record Official record
Conditions
Chronic Hepatitis C Virus
Interventions
VX-222, telaprevir, ribavirin
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 70 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
18
States / cities
Birmingham, Alabama • Anaheim, California • Riverside, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 4, 2014 · Synced Oct 25, 2026, 4:17 AM EDT
Not yet recruiting Not applicable Interventional

A Well-Being Intervention for People With IBS

NCT07600047
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Well-Being Intervention
Behavioral
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 25, 2026, 4:17 AM EDT
No Longer Available No phase listed Expanded access

Study of the Use of [18F]-DOPA in Hyperinsulinemic Hypoglycemia

NCT02533219
View directory record Official record
Conditions
Hyperinsulinemic Hypoglycemia, Persistent, Congenital Hyperinsulinism, Persistent Hyperinsulinemic Hypoglycemia of Infancy (PHHI)
Interventions
18 F-DOPA
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Up to 64 Years
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 7, 2020 · Synced Oct 25, 2026, 4:17 AM EDT
Completed No phase listed Observational

Metabolomics for Biomarker Discovery in Children With EoE

NCT03107819
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Plasma and urine metabolomics
Diagnostic Test
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
2 Years to 18 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 1, 2018 · Synced Oct 25, 2026, 4:17 AM EDT
Recruiting Phase 1 Interventional

Intra-tumoral (IT) Injection of vvDD-hIL2-2-RG-1 for Metastatic Gastrointestinal and Peritoneal Tumors

NCT07001592
View directory record Official record
Conditions
Gastric Neoplasms, Esophageal Cancer, Liver Cancer, Liver Metastasis, MSS-CRC, MSS, Gastric Adenocarcinoma, Peritoneal Cancer, Peritoneal Carcinoma, Peritoneal Metastases, MSI-H, Gastric Cancer
Interventions
vvDD-hIL-2-RG-1
Biological
Lead sponsor
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Other
Eligibility
18 Years to 69 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 3, 2025 · Synced Oct 25, 2026, 4:17 AM EDT